Screener
PBUS vs PBE
Invesco MSCI USA ETF vs Invesco Biotechnology & Genome ETF
Key differences
- PBUS costs 0.54% less per year.
- PBUS is significantly larger than PBE — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, PBUS has delivered higher annualized returns.
- PBE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| PBUS | PBE | |
|---|---|---|
| Annual cost (TER) | 0.04% | 0.58% |
| Fund size (AUM) | $10.7B | $247M |
| Since | 2017 | 2005 |
| Dividend yield | 1.03% | 1.09% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +30.6% | +35.8% |
| CAGR 3Y | +23.2% | +10.3% |
| CAGR 5Y | +14.0% | +3.5% |
| Sharpe 3Y | 1.23 | 0.41 |
| Volatility 1Y | 12.22% | 18.63% |
| Max drawdown | -33.15% | -37.84% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PBUS and PBE
Explore further